Scholarlink

<p>Glioblastoma (GBM), a highly aggressive form of glioma, poses serious harm to patients due to its extremely poor prognosis and severe resistance to chemotherapeutic agents. Although programmed necrosis (necroptosis) has been implicated in GBM progression, its precise function and biological significance in GBM remain incompletely defined. Here, we show that elevated expression of key necroptotic machinery proteins, including RIPK1 and MLKL, is positively associated with disease progression and predicts poor prognosis in glioma patients. Functionally, RIPK1 promotes glioblastoma cell proliferation, migration, and invasion. Genetic ablation of RIPK1 induces cell-cycle arrest and suppresses tumor growth in subcutaneous xenograft models, whereas pharmacological inhibition of RIPK1 with necrostatin-1 fails to restrict GBM cell expansion, suggesting that RIPK1 exerts oncogenic effects independent of its canonical necroptotic role. Notably, dual apoptosis- and necroptosis-inducing agents, ZZW115 and citronellol, synergize with temozolomide (TMZ)—the first-line chemotherapy for GBM—to enhance glioma cell death and increase tumor clearance in an orthotopic mouse glioma model. Collectively, these findings identify RIPK1 as a critical driver of glioma malignancy and underscore the therapeutic potential of activating necroptosis to augment TMZ efficacy, providing a framework for novel prognostic and treatment strategies in glioma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Necroptotic signaling orchestrates glioblastoma malignancy and potentiates temozolomide response

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月22日

查看全文
  • Yuanyuan Li,
  • Yuxin Qiu,
  • Wenqing Gao,
  • Lu Geng,
  • Zerui Wu,
  • Teng Zhang,
  • Jiasong Pan,
  • Jianglong Lu,
  • Danfeng Zhang,
  • Adi Idris,
  • Lijun Hou,
  • Zhipeng Su,
  • Jixi Li

摘要

Glioblastoma (GBM), a highly aggressive form of glioma, poses serious harm to patients due to its extremely poor prognosis and severe resistance to chemotherapeutic agents. Although programmed necrosis (necroptosis) has been implicated in GBM progression, its precise function and biological significance in GBM remain incompletely defined. Here, we show that elevated expression of key necroptotic machinery proteins, including RIPK1 and MLKL, is positively associated with disease progression and predicts poor prognosis in glioma patients. Functionally, RIPK1 promotes glioblastoma cell proliferation, migration, and invasion. Genetic ablation of RIPK1 induces cell-cycle arrest and suppresses tumor growth in subcutaneous xenograft models, whereas pharmacological inhibition of RIPK1 with necrostatin-1 fails to restrict GBM cell expansion, suggesting that RIPK1 exerts oncogenic effects independent of its canonical necroptotic role. Notably, dual apoptosis- and necroptosis-inducing agents, ZZW115 and citronellol, synergize with temozolomide (TMZ)—the first-line chemotherapy for GBM—to enhance glioma cell death and increase tumor clearance in an orthotopic mouse glioma model. Collectively, these findings identify RIPK1 as a critical driver of glioma malignancy and underscore the therapeutic potential of activating necroptosis to augment TMZ efficacy, providing a framework for novel prognostic and treatment strategies in glioma.